Almirall sets up in Poland and Switzerland
Leading Spanish drugmaker Almirall, as part of its international expansion, has established an affiliate in Poland, to serve as a platform for taking a large part of the eastern European market. It notes that Poland is the sixth largest pharmaceutical market in Europe, with positive growth potential, and the new subsidiary - located in the capital Warsaw - is forecast to generate sales of 5.0 million euros ($7.8 million) this year, primarily from the group's range of dermatologic products.
At the same time, Almirall announced that it has consolidated a business unit in Switzerland, allowing it to further strengthen its position in the European market along with its existing subsidiaries in Germany, Austria, France, Portugal and the UK and Ireland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze